Every piece MicroCap Desk has published on Jaguar Health, newest first. Independent editorial — we take no compensation from the companies we cover.
Jaguar Health launched a strategic review of crofelemer amid heavy financing activity. Capital structure is the story.
Crofelemer's canine CID trial is the first real platform-extension shot. Human vs. veterinary economics are not the same model.
Sentiment labels reflect the Desk's directional view at the time each article was published and are not price targets, ratings, or investment advice. Microcap securities carry a high risk of loss. See our full Disclosure.